Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of gene polymorphisms on the response of methotrexate-based treatments.

European journal of clinical pharmacology - 9 May 2026

Esperón Patricia, Vital Marcelo, Giletti Andrea

Abstract excerpt

PURPOSE: Methotrexate (MTX) is a long-standing drug used to treat leukemia (at high doses to inhibit DNA/RNA synthesis) and rheumatoid arthritis (at low doses for anti-inflammatory effects). Its characteristic narrow therapeutic range, in terms of efficacy and safety associated with MTX, are important factors to consider when deciding whether to prescribe it. A major challenge in its use is interindividual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to MTHFR gene
Share to TYMS gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 42104114
DOI: 10.1007/s00228-026-04059-x

Genes

MTHFR
FPGS
TYMS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 15 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of gene polymorphisms on the response of methotrexate-based treatments.PMID 42104114Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis.Semantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapySemantic proximity Read ↗

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseSemantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

MTHFR 677T-1298C haplotype in acute lymphoblastic leukemia: Impact on methotrexate therapy.Semantic proximity Read ↗

The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.